MONDAY PHARMACOLOGY
282
A33
878.7
Role of caveolin-1 S-nitrosylation,
ubiquitination, and degradation in idiopathic pulmonary
arterial hypertension.
F.R. Bakhshi, M. Bonini, Z. Chen,
G.N. NieuwAmerongen, S. Comhair, S. Erzurum and R.D.
Minshall. Univ. of Illinois at Chicago and Cleveland Clin.
A34
878.8
Macrophages polarize during acute lung injury
and resolve lung vascular dysfunction through sphingosine 1
phosphate.
S. Sukriti, K.R. Chava, M. Tauseef and R. Sadikot.
Univ. of Illinois at Chicago.
A35
878.9
Statins inhibit NADPH oxidase activity by
interference with membrane raft clustering independent of
Rac1 inactivation in endothelial cells.
Y. Zhang, X. Li and P-L.
Li. Virginia Commonwealth Univ.
A36
878.10 Impaired caveolin-1 contributes to hepatic
ischemia and reperfusion injury via suppression of sphingosine
kinase/sphingosine-1-phosphate receptor pathway.
J-W. Kang,
S. Pyo and S-M. Lee. Sch. of Pharm., Sungkyunkwan Univ.,
South Korea.
879. MUSCLE PHARMACOLOGY
Poster
m
on
. 7:30
am
—B
oston
C
onvention
& e
xhiBition
C
enter
,
e
xhiBit
h
alls
a-B
Presentation time: 12:30
pm
-2:30
pm
A37
879.1
The role of S-nitrosylated profilin-1 and myosin
regulatory light chain 9 in human myometrial contractile
dynamics.
S.D. Barnett, C. Ulrich, J. Baker and I.L.O. Buxton.
Univ. of Nevada, Reno.
A38
879.2
Bendroflumethiazide a potent opener of
human BK channel: a new perspective for an old drug in the
treatment of periodic paralysis.
G. Cannone, S. Calzolaro, A.
Mele, G.M. Camerino, M.M. Dinardo, R. Latorre, D.C. Conte
and D. Tricarico. Univ. of Bari, Italy and Univ. of Valparaiso,
Chile.
A39
879.3
Rescue of lethal CaV
b2 knock-out and
identification of novel CaV
b2 variants. P.E. Weissgerber, E.
Roth, S. Buchholz, F. Schmitz, V. Flockerzi and S. Kahl. Univ.
of Saarland and German Diabetes Ctr., Düsseldorf.
A40
879.4
Overexpression of the large-conductance,
Ca
2+
-activated K
+
(BK) channel shortens action potential
duration in HL-1 cardiomyocytes.
S.W. Rhee, L. Song, M.
Steephan, N.J. Rusch and J.R. Stimers. Univ. of Arkansas for
Med. Sci.
A41
879.5
Withapysalin induced cardiac positive
inotropism: in vitro and in vivo studies.
N.R. Nascimento, L.S.
Amorim, V.M. Gomes, C.F. Santos and M.C. Fonteles. Ceara
State Univ., Brazil.
A42
879.6
The myofilament Ca
2+
sensitizer levosimendan
maintains systolic function in volume overload heart failure in
rats.
K. Lewis, A. Guggilam, A.J. Trask, M.J. Cismowski and
P.A. Lucchesi. The Ohio State Univ. and Nationwide Children’s
Hosp.
A43
879.7
Heterogeneity of ATP-sensitive K
+
channels in
cardiac myocytes: enrichment at the intercalated disk.
M. Hong,
L. Bao, E. Kefaloyianni, E. Agullo-Pascual, H. Chkourko, M.
Foster, E. Taskin, D.A. Reid, E. Rothenberg, M. Delmar and
W.A. Coetzee. NYU Sch. of Med.
A44
879.8
A novel ruthenium nitrosyl complex ameliorates
L-NAME-induced bladder dysfunction.
C.F. Santos, R.M.
Campos, N.R.F. Nascimento and M.C. Fonteles. Ceara State
Univ., Brazil.
A45
879.9
Piperidine and pyridine alkaloid actions at fetal
muscle-type nicotinic acetylcholine receptors.
B.T. Green, K.D.
Welch, S.T. Lee, J.A. Pfister and K.E. Panter. USDA, Logan,
UT.
A46
879.10
b-arrestin2 expression is localized in cholinergic
but not nitrergic motor neurons in the mouse longitudinal
muscle-myenteric plexus.
H.T. Maguma, I.J. Ali, W.L. Dewey
and H.I. Akbarali. Virginia Commonwealth Univ. and Virginia
Commonwealth Univ.
880. ARACHIDONATE PRODUCTS IN VASCULAR
CONTROL
Poster
m
on
. 7:30
am
—B
oston
C
onvention
& e
xhiBition
C
enter
,
e
xhiBit
h
alls
a-B
Presentation time: 12:30
pm
-2:30
pm
A47
880.1
A novel epoxyeicosatrienoic acid analog
attenuates hypertension and renal injury in Cyp2c44 KO mice.
M.A.H. Khan, J.R. Falck and J.D. Imig. Med. Col. of Wisconsin,
Univ. of Texas Southwestern Med. Ctr.
A48
880.2
Proteinase-activated receptors, PAR1 and
PAR2, regulate porcine coronary contractility via tyrosine
kinase-MAPKinase signaling involving a cyclooxygenase-1
product.
M. El-Daly, M. Saifeddine, C.R. Triggle and M.D.
Hollenberg. Univ. of Calgary Fac. of Med., Canada and Weill
Cornell Med. Col.-Qatar.
A49
880.3
Inducible endothelium-derived hyperpolarizing
factor: a new role for the endothelial 15-lipoxygenase pathway.
W.B. Campbell, K.M. Gauthier and S.L. Pfister. Med. Col. of
Wisconsin.
A50
880.4
Prostaglandin E
2
, a postulated astrocyte-
derived neurovascular coupling agent, constricts rather than
dilates parenchymal arterioles.
F. Dabertrand, R.M. Hannah,
J.M. Pearson, D.C. Hill-Eubanks, J.E. Brayden and M.T.
Nelson. Univ. of Vermont Col. of Med.
A51
880.5
Angiotensin II receptor synergism with
prostaglandin E
2
receptors.
M.C. Palazzo and R.M. Breyer.
Vanderbilt Univ.
A52
880.6
Participation of cyclooxygenase and PGs E2
and F2
a during the development of the rat in the contractile
effect of phenylephrine in rat aorta and coronary artery.
N.
Acevedo-Villavicencio, E. Lopez-Calderon, I. Ramirez-
Sachez, G. Guevara-Balcazar and M.C. Castillo-Hernandez.
Sch. of Med. IPN, Mexico City.
881. GPCR OLIGOMERIZATION
Poster
m
on
. 7:30
am
—B
oston
C
onvention
& e
xhiBition
C
enter
,
e
xhiBit
h
alls
a-B
Presentation time: 12:30
pm
-2:30
pm
A53
881.1
Investigation of the D
1
-D
2
dopamine receptor
heteromer reveals a complex signaling mechanism not limited
to G
q
protein activation.
L.S. Chun, R.B. Free, T.B. Doyle, X-P.
Huang and D.R. Sibley. NINDS, NIH, Johns Hopkins Univ. and
Univ. of North Carolina Sch. of Med.
A54
881.2
Investigation of the novel pharmacology of
neuropeptide Y receptor dimers constrained by bimolecular
fluorescence complementation.
L. Kilpatrick and N. Holliday.
Univ. of Nottingham.
PHARMACOLOGY MONDAY
283
M
O
N
A55
881.3
Dimerization of G-protein coupled receptors
in appetite regulation and food reward.
H. Schellekens, T.G.
Dinan and J.F. Cryan. Sch. of Pharm., University Col. Cork
and Food for Hlth. Ireland, Cork.
A56
881.4
Functional interaction between mGluR1 and 5.
T. Sevastyanova and P. Kammermeier. Univ. of Rochester.
882. GPCR SIGNALING SCAFFOLDS AND
CROSSTALK
Poster
m
on
. 7:30
am
—B
oston
C
onvention
& e
xhiBition
C
enter
,
e
xhiBit
h
alls
a-B
Presentation time: 12:30
pm
-2:30
pm
A57
882.1
Role of the dopamine D3 receptor signaling
complex in the receptor tolerance and slow response
termination properties.
K. Kota. UMDNJ, Secaucus.
A58
882.2
Cross-talk between beta and alpha2 adrenergic
receptors in sympathetic neurons relies on protein kinase A
and spinophilin.
C. Cottingham, R. Lu and Q. Wang. Univ. of
Alabama at Birmingham.
A59
882.3
The dopamine receptor-interacting protein
S100B: consequences and site of binding.
K.A. Neve, H-J.
Lee, D. Buck and Y. Liu. VA Med. Ctr. and Oregon Hlth. & Sci.
Univ.
A60
882.4
Functional characterization of cannabinoid
receptor-interacting protein CRIP1a.
D.E. Selley, J.C. Jacob,
T.H. Smith, L.C. Blume, H. Shim, A. Straiker, K. Mackie,
A.C. Howlett, L.J. Sim-Selley and C-K. Chen. Virginia
Commonwealth Univ., Wake Forest Univ. and Indiana Univ.
A61
882.5
A-kinase anchoring proteins regulate
airway smooth muscle secretory function.
W.J. Poppinga,
A. Oldenburger, L.J. Holtzer, S. Driessen, I.H. Heijink, H.
Maarsingh and M. Schmidt. Univ. of Groningen, Univ. Med.
Ctr. Groningen, Netherlands and Max Delbrück Ctr. for Molec.
Med., Berlin.
A62
882.6
Structure-function relationship and local
subcellular signaling using heart failure relevant molecular
defined muscle specific mAKAP mutants.
A. Rababah, J.
Craft, S. Singh, F. Atrooz, C. Wijaya and B. McConnell. Univ.
of Houston.
A63
882.7
Serotonin transactivation of PDGF
b receptors
results in a heterologous desensitization to subsequent
transactivation stimuli.
M.A. Beazely and J.S. Kruk. Sch. of
Pharm., Univ. of Waterloo, Canada.
A64
882.8
Characterizing the structural elements involved
in
b1-adrenergic receptor interaction with SAP97. M.M. Nooh
and S.W. Bahouth. Cairo Univ. Fac. of Pharm. and Univ. of
Tennessee Hlth. Sci. Ctr., Memphis.
883. GPCR STRUCTURE AND FUNCTION
Poster
m
on
. 7:30
am
—B
oston
C
onvention
& e
xhiBition
C
enter
,
e
xhiBit
h
alls
a-B
Presentation time: 12:30
pm
-2:30
pm
A65
883.1
Function of the first intracellular loop for human
D1 and D5 dopaminergic receptors.
B. Zhang and M. Tiberi.
Ottawa Hosp. Res. Inst. and Univ. of Ottawa.
A66
883.2
CB1 cannabinoid receptor juxtamembrane
C-terminal phosphorylation in NT18TG2 cells.
K. Eldeeb, S.M.
Cowsik and A.C. Howlett. Wake Forest Univ. and Sch. of Life
Sci., Jawaharlal Nehru Univ.
A67
883.3
Role of the central region of the third
intracellular loop of human D1-class dopaminergic receptors.
A. Albaker, A. Charette, B. Liang, X. Yang and M. Tiberi.
Ottawa Hosp. Res. Inst. and Univ. of Ottawa.
A68
883.4
Conserved serines of transmembrane 5 in the
dopamine D
1
receptor interact with non-catechol D
1
ligands.
S-M. Lee, S. Bhattacharya, V. Nagarajan and R. Mailman.
Penn State, Hershey and Beckman Res. Inst. of City of Hope.
A69
883.5
The roles of tryptophan 69, aspartic acid 70
and tryptophan 72 in CGRP receptor signaling.
G. Kuteyi, J.
Barwell and D. Poyner. Aston Univ., U.K.
A70
883.6
Structure-function analysis of the ligand binding
pocket of bitter taste receptor T2R4.
S.P. Pydi, K. Nelson, M.
Loewen, R.P. Bhullar and P. Chelikani. Univ. of Manitoba and
Natl. Res. Council, Saskatoon.
884. ION CHANNEL NEUROPHARMACOLOGY
Poster
m
on
. 7:30
am
—B
oston
C
onvention
& e
xhiBition
C
enter
,
e
xhiBit
h
alls
a-B
Presentation time: 12:30
pm
-2:30
pm
A71
884.1
Activation of
a7 nicotinic acetylcholine receptor
protects M2 macrophages from ER stress-induced apoptosis.
R.H. Lee and G. Vazquez. Univ. of Toledo Col. of Med.
A72
884.2
Identifying the
a7-nicotinic acetylcholine
receptor interactome from a human neuroblastoma cell line.
M.J. Mulcahy, F. Barrantes and E. Hawrot. Brown Univ. and
UCA-CONICET, Buenos Aires.
A73
884.3
Interdependent expression of P2X receptors in
the mouse kidney: P2X4-P2X7 receptor “cross-talk”.
R. Birch,
T. Scott-Ward, F.W.K. Tam, C.M. Peppiatt-Wildman, R.J.
Unwin and S.S.P. Wildman. Medway Sch. of Pharm., Univs.
of Kent and Greenwich, Imperial Col., Hammersmith Hosp. and
UCL Med. Sch., Royal Free Hosp., London.
A74
884.4
Pharmacological potentiators of TRPM5
channel activity.
S. Siehler, J. Reinhardt, M. Kaufmann,
I. Dzhura and G. Erdemli. Novartis Insts. for BioMed. Res.,
Basel and Cambridge, MA.
A75
884.5
Non-proton ligand activation is linked to the
ASIC3 calcium block site.
R.N. Johnson and E.B. Gonzales.
Univ. of North Texas Hlth. Sci. Ctr.
A76
884.6
Targeted delivery of Kv1.3 siRNAs with
functionalized lipid nanoparticles.
P. Hajdu, T. Thompson, Y.
Yun and L. Conforti. Univ. of Cincinnati and North Carolina
A&T State Univ.
A77
884.7
Hypo-osmolality pressor stimulus is linked to
transient receptor potential vanilloid 4 in the portal region.
T.
Mai, J. McHugh, A. Diedrich, E.M. Garland and D. Robertson.
Vanderbilt Univ. and Johns Hopkins Univ.
MONDAY PHARMACOLOGY
284
885. NEUROTRANSMITTER TRANSPORTERS
Poster
m
on
. 7:30
am
—B
oston
C
onvention
& e
xhiBition
C
enter
,
e
xhiBit
h
alls
a-B
Presentation time: 12:30
pm
-2:30
pm
A78
885.1
Amphetamine potentiates NMDA receptor
currents in midbrain dopamine neurons.
S.L. Ingram, M. Li,
S.M. Underhill and S.G. Amara. Oregon Hlth. & Sci. Univ. and
Univ. of Pittsburgh.
A79
885.2
Methylene
dioxy
pyrovalerone is a potent
inhibitor of hDAT and hNET.
E. Solis, K.N. Cameron,
R. Kolanos, R.A. Glennon and L.J. De Felice. Virginia
Commonwealth Univ.
A80
885.3
Methamphetamine and amphetamine
influence biophysical properties of dopamine transporter in a
phosphorylation-dependent manner.
P. Davari, L. Villarroel, K.
Saha, E. Cartier and H. Khoshbouei. Univ. of Florida.
A81
885.4
Amphetamine and methamphetamine
differentially regulate biophysical properties of dopamine
transporter.
K. Saha, L. Villarroel, P. Davari, S.E. Mehr, M.R.
Zarindast, B. Richardson and H. Khoshbouei. Univ. of
Florida and Tehran Univ. of Med. Sci.
886. OPIOIDS AND PAIN
Poster
m
on
. 7:30
am
—B
oston
C
onvention
& e
xhiBition
C
enter
,
e
xhiBit
h
alls
a-B
Presentation time: 12:30
pm
-2:30
pm
A82
886.1
Effects of methadone, fentanyl and nalbuphine
on intracranial self-stimulation in rats: modulation by morphine
exposure.
A. Altarifi and S.S. Negus. Virginia Commonwealth
Univ.
A83
886.2
Role of phosphodiesterase-4 in alcohol- and
heroin-seeking behavior.
H-T. Zhang, M-J. Lai, R-T. Wen, M-F.
Gong, W. Hu and W-H. Zhou. West Virginia Univ. Hlth. Sci. Ctr.,
Sch. of Med., Ningbo Univ., China and Peking Univ., Beijing.
A84
886.3
Examining the reinforcing properties of NOP
receptor agonist SCH221510 and its role in attenuating mu
receptor-mediated reinforcement in a rat self-administration
assay.
D. Sukhtankar, C.H. Lagorio and M-C. Ko. Univ. of
Michigan Med. Sch. and Univ. of Wisconsin-Eau Claire.
A85
886.4
Assessing the decay of heterologous tolerance
to morphine after varying lengths of treatment via intraperitoneal
injection.
B.G. Thompson, J.M. Masterson and D.A. Taylor.
Brody Sch. of Med. East Carolina Univ.
A86
886.5
Selective effects of a morphine conjugate
vaccine on heroin and metabolite distribution and heroin-
induced behaviors in rats.
M.D. Raleigh, M. Pravetoni, A.C.
Harris, A.K. Birnbaum and P.R. Pentel. Univ. of Minnesota,
Minneapolis and Minneapolis Med. Res. Fndn.
A87
886.6
A single exposure to morphine induces long-
lasting sensitization: age-related differences in mice.
W. Koek.
Univ. of Texas Hlth. Sci. Ctr. at San Antonio.
A88
886.7
Behavioral effects of oxycodone following
traumatic brain injury in rats.
K.L. Nicholson, M.A. Greenwood,
N.L. Day, R.M. Lockhart, K.L. Shelton and C.L. Floyd. Virginia
Commonwealth Univ. and Univ. of Alabama at Birmingham.
A89
886.8
Role of spinal cord endogenous opioid peptides
in the antinociceptive effect of hyperbaric oxygen.
J. Heeman,
Y. Zhang, D.Y. Shirachi and R.M. Quock. Washington State
Univ. and Univ. of Pacific.
A90
886.9
Effects of the cannabinoid 2 receptor-selective
agonist GW405833 in assays of acute pain-stimulated and
pain-depressed behavior in rats.
A. Kwilasz and S. Negus.
Virginia Commonwealth Univ.
A91
886.10 Pain-related depression of the mesolimbic
dopamine system in rats.
M. Leitl, M.L. Banks and S.S.
Negus. Vifginia Commonwealth Univ. Sch. of Med.
A92
886.11 Effects of neonatal visceral pain on morphine
tolerance, dependence, and withdrawal in rats.
A.P. Norwood
and W.E. Fantegrossi. Univ. of Arkansas for Med. Sci.
A93
886.12 Putative pain-like states alter the discriminative
stimulus effects of morphine in mice dependent on sex.
H.
Neelakantan, S.J. Ward and E.A. Walker. Temple Univ.
A94
886.13 Effects of imidazoline I2 receptor agonists in
rat models of chronic pain.
J-X. Li, D.A. Thorn and Y. Zhang.
Univ. at Buffalo and Res. Triangle Inst., Durham, NC.
A95
886.14 Antinociceptive effects of
a7 nicotinic
acetylcholine receptor positive allosteric modulators type I and
II in models of acute and chronic pain in mice.
K. Freitas, S.S.
Negus, F.I. Carroll and M.I. Damaj. Virginia Commonwealth
Univ. and Res. Triangle Inst.
A96
886.15 The role of the kappa-opioid receptor on age-
specific behaviors induced from co-administration of alcohol
and nicotine.
A. Larraga, J.D. Belluzzi and F.M. Leslie. Univ.
of California, Irvine.
887. PAIN
Poster
m
on
. 7:30
am
—B
oston
C
onvention
& e
xhiBition
C
enter
,
e
xhiBit
h
alls
a-B
Presentation time: 12:30
pm
-2:30
pm
A97
Dostları ilə paylaş: |